1. CAR (Chimeric Antigen Receptors) T-Cell Therapy for Treatment of Hematologic Cancers
View the Original Poster File: CAR (Chimeric Antigen Receptors) T-Cell Therapy for Treatment of Hematologic Cancers
CAR T-Cell therapy is a groundbreaking immunotherapy technique that utilizes patients own T cells to combat cancer. This method has shown remarkable success in treatment of certain Hematologic Cancers and provide new hope for patients over conventional therapies.
In this method, T cells are collected from the patients blood. Scientists add antibody like protein chimeric antigen receptors (CARs) to the T cells. CARs helps the T cell to recognize and attach with cancer cells. Then this CAR T-cells are harvested in the lab to make millions of copies, and injected in the patients bloodstream.
CAR T-cell therapy shows significant efficacy and precise targeting in treating acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
This therapy revolutionized the cancer treatment. Ongoing research focuses on addressing it’s limitations, reducing production costs and extending it’s applicability to solid tumors. This therapy also represents a promising step forward in personalised medicine.
Keywords: Cancer Treatment, CAR T-Cell therapy, ALL, DLBCL
.png)
View the Original Poster File: CAR (Chimeric Antigen Receptors) T-Cell Therapy for Treatment of Hematologic Cancers
Reference:
[1] De Marco, R. C., Monzo, H. J., & Ojala, P. M. (2023). CAR T Cell Therapy: A Versatile Living Drug. International journal of molecular sciences, 24(7), 6300. https://doi.org/10.3390/ijms24076300
[2] Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in immunology, 13, 927153. https://doi.org/10.3389/fimmu.2022.927153